TYK Medicines, Inc (Stock Code: 2410) held its 2025 second extraordinary general meeting (EGM) on October 30, 2025, in Shanghai. The meeting was chaired by the Chairman of the Board, and attended by all directors either in person or via electronic means. The EGM procedures were declared compliant with the PRC Company Law and the company’s articles of association.

The total number of issued shares as of the meeting date was 380,065,818, and holders of 133,137,502 shares submitted valid votes. This figure accounts for approximately 35.03% of the company’s total issued shares.

All proposed resolutions, including amendments to the Rules of Procedure for the Board of Directors, amendments to the Rules of Procedure for Shareholders’ General Meetings, amendments to the Articles of Association and abolishment of the Board of Supervisors, as well as adoption of the 2025 H Share Incentive Scheme, were duly passed. The vote results for each resolution met the required thresholds, with more than half of the votes cast in favor of each ordinary resolution and at least two-thirds of the votes cast in favor of each special resolution.

According to the announcement, no shareholders were required to abstain from voting at the EGM, and no shareholders voted against any resolutions. All relevant voting procedures were confirmed by the company’s H share registrar in Hong Kong, appointed as scrutineer for the poll.